Emerging treatment options for the mucopolysaccharidoses

References

• Neufeld E, Muenzer J. The mucopolysaccharidosis. In: Scriver CR, Beaudet AL, Sly WS, Valle D, editors. The Metabolic and Molecular Basis of Inherited Disease. New York: McGraw-Hill; 2001:3421–3451.
   Google Scholar
• Giugliani R, Federhen A, Munoz Rojas MV, et al. [Enzyme replacement therapy for mucopolysaccharidoses I, II and VI: recommendations from a group of Brazilian experts]. Rev Assoc Med Bras. 2010;56(3):257–277. Portuguese.
   Web of Science ®Google Scholar
• Beck M. Therapy for lysosomal storage disorders. IUBMB Life. 2010;62(1):33–40.
   PubMed Web of Science ®Google Scholar
• Valayannopoulos V, Wijburg FA. Therapy for the mucopolysaccharidoses. Rheumatology (Oxford). 2011;50 Suppl 5:v49-v59.
   Google Scholar
• Clarke LA, Wraith JE, Beck M, et al. Long-term efficacy and safety of laronidase in the treatment of mucopolysacchoaridosis I. Pediatrics. 2009;123(1):229–240.
   PubMed Web of Science ®Google Scholar
• Wraith JE, Scarpa M, Beck M, et al. Mucopolysaccharidosis type II (Hunter syndrome): a clinical review and recommendations for treatment in the era of enzyme replacement therapy. Eur J Pediatr. 2008;167(3):267–277.
   PubMed Web of Science ®Google Scholar
• Harmatz P Giugliani R, Schwartz IV, et al; MPS VI Study Group. Long-term follow-up of endurance and safety outcomes during enzyme replacement therapy for mucopolysaccharidosis VI: Final results of three clinical studies of recombinant human N-acetylgalactosamine 4-sulfatase. Mol Genet Metab. 2008;94(4):469–475.
   PubMed Web of Science ®Google Scholar
• Dickson P, Peinovich M, McEntee M, et al. Immune tolerance improves the efficacy of enzyme replacement therapy in canine mucopolysaccharidosis I. J Clin Invest. 2008;118(8):2868–2876.
   Web of Science ®Google Scholar
• Horovitz D, Magalhaes TSPC, Bonfim C, et al. Enzyme replacement therapy (ERT) and hematopoietic stem cell transplantation (HSCT) in a very young child with Hunter Syndrome: two year follow-up. Abstract: Proceedings of the 12th International Symposium on MPS and related diseases; June 28-July 1, 2012; Noordwijkerhout, The Netherlands: p. 103.
   Google Scholar
• Tomatsu S, Montano AM, Oikawa H, et al. Mucopolysaccharidosis type IVA (Morquio A disease): clinical review and current treatment. Curr Pharm Biotechnol. 2011;12(6):931–945.
   PubMed Web of Science ®Google Scholar
• Kakkis ED, Neufeld EF.. The mucopolysaccharidoses. In: Berg BO, editor. Principles of Child Neurology. New York: McGraw-Hill, 1996:1141–1165.
   Google Scholar
• Dvorak-Ewell M, Wendt D, Hague C, et al. Enzyme replacement in a human model of mucopolysaccharidosis IVA in vitro and its biodistribution in the cartilage of wild type mice. PLoS One. 16, 2010;5(8):e12194.
   Google Scholar
• Tomatsu S, Montano AM, Dung VC, et al. Enhancement of drug delivery: enzyme-replacement therapy for murine Morquio A syndrome. Mol Ther. 2010;18(6):1094–1102.
   Web of Science ®Google Scholar
• BioMarin. BioMarin provides update on GALNS Phase 1/2 Extension Study (M0R-100) [press release]. Novato, CA: Biomarin Pharmaceutical Inc; July 28, 2011. Available from: http://phx.corporate-ir.net/phoenix.zhtml?c=106657&p=irol-newsArticle&ID=1590497&highlight=. Accessed February 23, 2012.
   Google Scholar
• Sly WS, Quinton BA, McAlister WH, Rimoin DL. Beta glucuronidase deficiency: report of clinical, radiologic, and biochemical features of a new mucopolysaccharidosis. J Pediatr. 1973;82(2):249–257.
   PubMed Web of Science ®Google Scholar
• Sly WS. Enzyme replacement therapy: from concept to clinical practice. Acta Paediatr Suppl. 2002;91(439):71–78.
   PubMedGoogle Scholar
• Vogler C, Levy B, Grubb JH, et al. Overcoming the blood-brain barrier with high-dose enzyme replacement therapy in murine mucopolysaccharidosis VII. Proc Natl Acad Sci U S A. 2005;102(41):14777–14782.
   PubMed Web of Science ®Google Scholar
• National MPS Society. A Guide to Understanding MPS VII. Durham, NC: National MPS Society; 2008. Available from: http://www.mpssociety.org/wp-content/uploads/2011/07/MPS_VII_2008.pdf. Accessed February 23, 2012.
   Google Scholar
• Chen AH, Dickson PI. Enzyme replacement therapy for cognitive decline in mucopolysaccharidosis Type I: past, present, and future. Lysosomal Storage Diseases. 2011;9(1):9–16
   Google Scholar
• Auclair D, Finnie J, White J, et al. Repeated intrathecal injections of recombinant human-4-sulphatase remove dural storage in mature mucopolysaccharidosis VI cats primed with a short-course tolerisation regimen. Mol Gen Metab. 2010;99(2):132–141
   Web of Science ®Google Scholar
• Dickson PI, Hanson S, McEntee MF, et al. Early versus late treatment of spinal cord compression with long-term intrathecal enzyme replacement therapy in canine mucopolysaccharidosis type I. Mol Genet Metab. 2010;101(2–3):115–122
   PubMed Web of Science ®Google Scholar
• Kakkis E, Lester T,Yang R, et al. Successful induction of immune tolerance to enzyme replacement therapy in canine mucopolysaccharidosis I. Proc Natl Acad Sci U S A. 2004;101(3):829–834
   Web of Science ®Google Scholar
• Munoz-Rojas MV, Vieira T, Costa R, et al. Intrathecal enzyme replacement therapy in a patient with mucopolysaccharidosis type I and symptomatic spinal cord compression. Am J Med Genet A. 2008;146A(19):2538–2544.
   PubMed Web of Science ®Google Scholar
• Munoz-Rojas MV, Horovitz DD, Jardim LB, et al. Intrathecal administration of recombinant human N-acetylgalactosamine 4-sulfatase to a MPS VI patient with pachymeningitis cervicalis. Mol Genet Metab. 2010;99(4):346–350
   PubMed Web of Science ®Google Scholar
• Jakobkiewicz-Banecka J, Wegrzyn A, Wegrzyn G. Substrate deprivation therapy: a new hope for patients suffering from neuronopathic forms of inherited lysosomal storage diseases. JAppl Genet. 2007;48(4):383–388
   Web of Science ®Google Scholar
• Roberts AL. Substrate Deprivation as a Novel Therapy for the Mucopolysaccharidoses [doctoral thesis]. South Australia: University of Adelaide; 2007.
   Google Scholar
• Piotrowska E, Jakobkiewicz-Banecka J, Baranska S, et al. Genistein- mediated inhibition of glycosaminoglycan synthesis as a basis for gene expression-targeted isoflavone therapy for mucopolysaccharidoses. Eur J Hum Genet. 2006;14(7):846–852
   PubMed Web of Science ®Google Scholar
• Friso A, Tomanin R, Salvalaio M, Scarpa M. Genistein reduces gly- cosaminoglycan levels in a mouse model of mucopolysaccharidosis type II. Br J Pharmacol. 2010;159(5):1082–1091
   PubMed Web of Science ®Google Scholar
• Malinowska M, Wilkinson FL, Bennett W, et al. Genistein reduces lysosomal storage in peripheral tissues of mucopolysaccharide IIIB mice. Mol Genet and Metab. 2009;98(3):235–242
   PubMed Web of Science ®Google Scholar
• Malinowska M, Wilkinson FL, Langford-Smith KJ, et al. Genistein improves neuropathology and corrects behaviour in a mouse model of neurodegenerative metabolic disease. PLoS One. 2010;5(12):e14192.
   PubMed Web of Science ®Google Scholar
• Piotrowska E, Jakobkiewicz-Banecka J, Tylki-Szymanska A, et al. Genistin-rich soy isoflavone extract in substrate reduction therapy for Sanfilippo syndrome: an open-label, pilot study in 10 pediatric patients. Current Therapeutic Research. 2008;69(2):166–179
   PubMed Web of Science ®Google Scholar
• Tsai TH. Concurrent measurement of unbound genistein in the blood, brain and bile of anesthetized rats using microdialysis and its pharmacokinetic application. J Chromatogr A. 2005;1073(1–2):317–322
   Web of Science ®Google Scholar
• Akiyama T, Ishida J, Nakagawa S, et al. Genistein, a specific inhibitor of tyrosine-specific protein kinases. J Biol Chem. 1987;262(12):5592–5595
   PubMed Web of Science ®Google Scholar
• Kloska A, Jakobkiewicz-Banecka J, Narajczyk M, Banecka-Majkutewicz Z, Wegrzyn G. Effects of flavonoids on glycosaminoglycan synthesis: implications for substrate reduction therapy in Sanfilippo disease and other mucopolysaccharidoses. Metab Brain Dis. 2011;26(1):1–8
   PubMed Web of Science ®Google Scholar
• Wijburg FA, Valstar MJ, Ruijter de J. Genistein: results of clinical trials. Proceedings of the 12th International Symposium on MPS and related diseases; June 28–July 1, 2012; Noordwijkerhout, The Netherlands: p. 43.
   Google Scholar
• Bigger B. Genistein: animal studies and a new trial. 12th International Symposium on MPS and related diseases. Proceedings of the 12th International Symposium on MPS and related diseases; June 28-July 1, 2012; Noordwijkerhout, The Netherlands: p. 44.
   Google Scholar
• Kim K, Dodsworth C, Paras A, Burton BK. High dose synthetic genistein treatment in MPS patients with neurological involvement. Proceedings of the 12th International Symposium on MPS and related diseases; June 28-July 1, 2012; Noordwijkerhout, The Netherlands: p. 76.
   Google Scholar
• Kaji T, Kawashima T, Sakamoto M. Rhodamine B inhibition of glycosaminoglycan production by cultured human lip fibroblasts. Toxicol Appl Pharmacol. 1991;111(1):82–89.
   Web of Science ®Google Scholar
• Roberts AL, Thomas BJ, Wilkinson AS, Fletcher JM, Byers S. Inhibition of glycosaminoglycan synthesis using rhodamine B in a mouse model of mucopolysaccharidosis type IIIA. Pediatr Res. 2006;60(3):309–314.
   PubMed Web of Science ®Google Scholar
• Roberts AL, Rees MH, Klebe S, Fletcher JM, Byers S. Improvement in behaviour after substrate deprivation therapy with rhodamine B in a mouse model of MPS IIIA. Mol Genet Metab. 2007;92(1–2):115–121.
   PubMed Web of Science ®Google Scholar
• Roberts AL, Fletcher JM, Moore L, Byers S. Trans-generational exposure to low levels of rhodamine B does not adversely affect litter size or liver function in murine mucopolysaccharidosis type IIIA. Mol Genet Metab. 2010;101(2–3):208–213.
   Web of Science ®Google Scholar
• Fan JQ, Ishii S. Active-site-specific chaperone therapy for Fabry disease. Yin and Yang of enzyme inhibitors. FEBS J. 2007;274(19):4962–4971.
   Google Scholar
• Parenti G. Treating lysosomal storage diseases with pharmacological chaperones: from concept to clinics. EMBO Mol Med. 2009;1(5):268–279.
   PubMed Web of Science ®Google Scholar
• Schiffmann R. Therapeutic approaches for neuronopathic lysosomal storage disorders. J Inherit Metab Dis. 2010;33(4):373–379.
   PubMed Web of Science ®Google Scholar
• Lim-Melia ER, Kronn DF. Current enzyme replacement therapy for the treatment of lysosomal storage diseases. Pediatr Ann. 2009;38(8):448–455.
   Web of Science ®Google Scholar
• Valenzano KJ, Khanna R, Powe AC, et al. Identification and characterization of pharmacological chaperones to correct enzyme deficiencies in lysosomal storage disorders. Assay Drug Dev Technol. 2011;9(3):213–235.
   PubMed Web of Science ®Google Scholar
• Fan JQ, Ishii S, Asano N, Suzuki Y. Accelerated transport and maturation of lysosomal alpha-galactosidase A in Fabry lymphoblasts by an enzyme inhibitor. Nat Med. 1999;5(1):112–115.
   PubMed Web of Science ®Google Scholar
• Germain DP, Fan JQ. Pharmacological chaperone therapy by active-site- specific chaperones in Fabry disease: in vitro and preclinical studies. Int J Clin Pharmacol Ther. 2009;47 Suppl 1:S111-S117.
   Google Scholar
• Beck M. Emerging drugs for lysosomal storage diseases. Expert Opin Emerg Drugs. 2010;15(3):495–507.
   PubMed Web of Science ®Google Scholar
• Loo TW, Clarke DM. Chemical and pharmacological chaperones as new therapeutic agents. Expert Rev Mol Med. 2007;9(16):1–18.
   PubMedGoogle Scholar
• Porto C, Cardone M, Fontana F, et al. The pharmacological chaperone N-butyldeoxynojirimycin enhances enzyme replacement therapy in Pompe disease fibroblasts. Mol Ther. 2009;17(6):964–971.
   PubMed Web of Science ®Google Scholar
• de Ruijter J, Valstar MJ, Wijburg FA. Mucopolysaccharidosis type III (Sanfilippo Syndrome): emerging treatment strategies. Curr Pharm Biotechnol. 2011;12(6):923–930.
   PubMed Web of Science ®Google Scholar
• Feldhammer M, Durand S, Pshezhetsky AV. Protein misfolding as an underlying molecular defect in mucopolysaccharidosis III type C. PLoS One. 2009;4(10):e7434.
   PubMed Web of Science ®Google Scholar
• Suzuki Y, Ogawa S, Sakakibara Y. Chaperone therapy for neuronopathic lysosomal diseases: competitive inhibitors as chemical chaperones for enhancement of mutant enzyme activities. Perspect Medicin Chem. 2009;3:7–19.
   Google Scholar
• Wilschanski M, Yahav Y, Yaacov Y, et al. Gentamicin-induced correction of CFTR function in patients with cystic fibrosis and CFTR stop mutations. N Engl J Med. 2003;349(15):1433–1441.
   PubMed Web of Science ®Google Scholar
• Linde L, Kerem B. Introducing sense into nonsense in treatments of human genetic diseases. Trends Genet. 2008;24(11):552–563.
   PubMed Web of Science ®Google Scholar
• Keeling KM, Bedwell DM. Clinically relevant aminoglycosides can suppress disease-associated premature stop mutations in the IDUA and P53 cDNAs in a mammalian translation system. J Mol Med (Berl). 2002;80(6):367–376.
   Web of Science ®Google Scholar
• Hein LK, Bawden M, Muller VJ, Sillence D, Hopwood JJ, Brooks DA. Alpha-L-iduronidase premature stop codons and potential read- through in mucopolysaccharidosis type I patients. J Mol Biol. 2004;338(3):453–462.
   PubMed Web of Science ®Google Scholar
• Menon KP, Neufeld EF. Evidence for degradation of mRNA encoding alpha-L-iduronidase in Hurler fibroblasts with premature termination alleles. Cell Mol Biol (Noisy-le-grand). 1994;40(7):999–1005.
   Web of Science ®Google Scholar
• Lualdi S, Di Rocco M, Corsolini F, et al. Identification of nine new IDS alleles in mucopolysaccharidosis II. Quantitative evaluation by real-time RT-PCR of mRNAs sensitive to nonsense-mediated and nonstop decay mechanisms. Biochim Biophys Acta. 2006;1762(4):478–484.
   PubMed Web of Science ®Google Scholar
• Linde L, Boelz S, Nissim-Rafinia M, et al. Nonsense-mediated mRNA decay affects nonsense transcript levels and governs response of cystic fibrosis patients to gentamicin. J Clin Invest. 2007;117(3):683–692.
   PubMed Web of Science ®Google Scholar
• Keeling KM, Brooks DA, Hopwood JJ, Li P, Thompson JN, Bedwell DM. Gentamicin-mediated suppression of Hurler syndrome stop mutations restores a low level of alpha-L-iduronidase activity and reduces lysosomal glycosaminoglycan accumulation. Hum Mol Genet. 2001;10(3):291–299.
   Web of Science ®Google Scholar
• Wang D, Belakhov V, Kandasamy J, et al. The designer aminoglycoside NB84 significantly reduces glycosaminoglycan accumulation associated with MPS I-H in the Idua-W392X mouse. Mol GenetMetab. 2012;105(1):116–125.
   Google Scholar
• Chung S, Ma X, Liu Y, Lee D, Tittiger M, Ponder KP. Effect of neonatal administration of a retroviral vector expressing alpha-L-iduronidase upon lysosomal storage in brain and other organs in mucopolysaccharidosis I mice. Mol Genet Metab. 2007;90(2):181–192.
   Web of Science ®Google Scholar
• Visigalli I, Delai S, Politi LS, et al. Gene therapy augments the efficacy of hematopoietic cell transplantation and fully corrects mucopolysaccharidosis type I phenotype in the mouse model. Blood. 2010;116(24):5130–5139.
   PubMed Web of Science ®Google Scholar
• Camassola M, Braga LM, Delgado-Cañedo A, et al. Nonviral in vivo gene transfer in the mucopolysaccharidosis I murine model. J Inherit Metab Dis. 2005;28(6):1035–1043.
   Web of Science ®Google Scholar
• Richard M, Arfi A, Seguin J, Gandolphe C, Scherman D. Widespread biochemical correction of murine mucopolysaccharidosis type VII pathology by liver hydrodynamic plasmid delivery. Gene Ther. 2009;16(6):746–756.
   Web of Science ®Google Scholar
• Osborn MJ, McElmurry RT, Lees CJ, et al. Minicircle DNA-based gene therapy coupled with immune modulation permits long-term expression of a-L-iduronidase in mice with mucopolysaccharidosis type I. Mol Ther. 2011;19(3):450–460.
   PubMed Web of Science ®Google Scholar
• Aronovich EL, Bell JB, Khan SA, et al. Systemic correction of storage disease in MPS I NOD/SCID mice using the sleeping beauty transposon system. Mol Ther. 2009;17(7):1136–1144.
   PubMed Web of Science ®Google Scholar
• Baldo G, Quoos Mayer F, Burin M, Carrillo-Farga J, Matte U, Giugliani R. Recombinant encapsulated cells overexpressing alpha-L-iduronidase correct enzyme deficiency in human mucopolysaccharidosis type I cells. Cells Tissues Organs. 2012;195(4):323–329.
   Web of Science ®Google Scholar
• Piller Puicher E, Tomanin R, Salvalaio M, et al. Encapsulated engineered myoblasts can cure Hurler syndrome: preclinical experiments in the mouse model. Gene Therapy. 2012;19(4):355–364.
   Web of Science ®Google Scholar
• Baldo G, Mayer FQ, Martinelli B, et al. Intraperitoneal implant of recombinant encapsulated cells overexpressing alpha-l-iduronidase partially corrects visceral pathology in mucopolysaccharidosis type I mice. Cytotherpy. 2012;14(7):860–867.
   PubMed Web of Science ®Google Scholar
• Friso A, Tomanin R, Alba S, et al. Reduction of GAG storage in MPS II mouse model following implantation of encapsulated recombinant myoblasts. J Gene Med. 2005;7(11):1482–1491.
   PubMed Web of Science ®Google Scholar
• Ross CJ, Bastedo L, Maier SA, Sands MS, Chang PL. Treatment of a lysosomal storage disease, mucopolysaccharidosis VII, with microencapsulated recombinant cells. Hum Gene Ther. 2000;11(15):2117–2127.
   PubMed Web of Science ®Google Scholar
• Ross CJ, Ralph M, Chang PL. Somatic gene therapy for a neurodegenerative disease using microencapsulated recombinant cells. Exp Neurol. 2000;166(2):276–286.
   Web of Science ®Google Scholar
• Hacein-Bey-Abina S, von Kalle C, Schmidt M, et al. A serious adverse event after successful gene therapy for X-linked severe combined immunodeficiency. N Engl J Med. 2003;348(3):255–256.
   PubMed Web of Science ®Google Scholar
• Mango RL, Xu L, Sands MS, et al. Neonatal retroviral vector-mediated hepatic gene therapy reduces bone, joint, and cartilage disease in mucopolysaccharidosis VII mice and dogs. Mol Genet Metab. 2004;82(1):4–19.
   Web of Science ®Google Scholar
• Baldo G, Wu S, Howe RA, et al. Pathogenesis of aortic dilatation in mucopolysaccharidosis VII mice may involve complement activation. Mol Genet Metab. 2011;104(4):608–619.
   PubMed Web of Science ®Google Scholar
• Herati RS, Ma X, Tittiger M, Ohlemiller KK, Kovacs A, Ponder KP Improved retroviral vector design results in sustained expression after adult gene therapy in mucopolysaccharidosis I mice. J Gene Med. 2008;10(9):972–982.
   Web of Science ®Google Scholar
• McIntyre C, Derrick Roberts AL, Ranieri E, Clements PR, Byers S, Anson DS. Lentiviral-mediated gene therapy for murine mucopolysaccharidosis type IIIA. Mol Genet Metab. 2008;93(4):411–418.
   PubMed Web of Science ®Google Scholar
• Di Natale P, Di Domenico C, Di Napoli D. Serum MIP-1 alpha level: a biomarker for the follow-up of lentiviral therapy in mucopolysaccharidosis IIIB mice. J Inherit Metab Dis. 2010;33(2):159–165.
   Web of Science ®Google Scholar
• Bielicki J, McIntyre C, Anson DS. Comparison of ventricular and intravenous lentiviral-mediated gene therapy for murine MPS VII. Mol Genet Metab. 2010;101(4):370–382.
   PubMed Web of Science ®Google Scholar
• Ruzo A, Garcia M, Ribera A, et al. Liver production of sulfamidase reverses peripheral and ameliorates CNS pathology in mucopolysaccharidosis IIIA mice. Mol Ther. 2012;20(2):254–266.
   Web of Science ®Google Scholar
• Cotugno G, Annunziata P, Tessitore A, et al. Long-term amelioration of feline Mucopolysaccharidosis VI after AAV-mediated liver gene transfer. Mol Ther. 2011;19(3):461–469.
   PubMed Web of Science ®Google Scholar
• Fu H, Kang L, Jennings JS, et al. Significantly increased lifespan and improved behavioral performances by rAAV gene delivery in adult mucopolysaccharidosis IIIB mice. Gene Ther. 2007;14(14):1065–1077.
   Web of Science ®Google Scholar
• Ellinwood NM, Ausseil J, Desmaris N, et al. Safe, efficient, and reproducible gene therapy of the brain in the dog models of Sanfilippo and Hurler syndromes. Mol Ther. 2011;19(2):251–259.
   PubMed Web of Science ®Google Scholar
• Heldermon CD, Ohlemiller KK, Herzog ED, et al. Therapeutic efficacy of bone marrow transplant, intracranial AAV-mediated gene therapy, or both in the mouse model of MPS IIIB. Mol Ther. 2010;18(5):873–880.
   PubMed Web of Science ®Google Scholar
• Kim S. Genetically engineered human neural stem cells for brain repair in neurological diseases. Brain Dev. 2007;29(4):193–201.
   PubMed Web of Science ®Google Scholar
• Shihabuddin LS, Cheng SH. Neural stem cell transplantation as a therapeutic approach for treating lysosomal storage diseases. Neurotherapeutics. 2011;8(4):659–667.
   PubMed Web of Science ®Google Scholar
• Snyder EY, Taylor RM, Wolfe JH. Neural progenitor cell engraftment corrects lysosomal storage throughout the MPS VII mouse brain. Nature. 1995;374(6520):367–370.
   PubMed Web of Science ®Google Scholar
• Meng XL, Shen JS, Ohashi T, Maeda H, Kim S, Eto Y. Brain transplantation of genetically engineered human neural stem cells globally corrects brain lesions in the mucopolysaccharidosis type VII mouse. J Neurosci Res. 2003;74(2):266–277.
   Web of Science ®Google Scholar
• Eto Y, Shen JS, Meng XL, Ohashi T. Treatment of lysosomal storage disorders: cell therapy and gene therapy. J Inherit Metab Dis. 2004;27(3):411–415.
   Web of Science ®Google Scholar
• Fukuhara Y, Li XK, Kitazawa Y, et al. Histopathological and behavioral improvement of murine mucopolysaccharidosis type VII by intracerebral transplantation of neural stem cells. Mol Ther. 2006;13(3):548–555.
   Web of Science ®Google Scholar
• Sidman RL, Li J, Stewart GR, Clarke J, Yang W, Snyder EY, Shihabuddin LS. Injection of mouse and human neural stem cells into neonatal Niemann-Pick A model mice. Brain Res. 2007;1140:195–204.
   PubMed Web of Science ®Google Scholar
• Feng Z, Gao F Stem cell challenges in the treatment of neurodegenerative disease. CNSNeurosci Ther. 2012;18(2):142–148.
   PubMed Web of Science ®Google Scholar
• Meng XL, Shen JS, Kawagoe S, Ohashi T, Brady RO, Eto Y. Induced pluripotent stem cells derived from mouse models of lysosomal storage disorders. Proc Natl Acad Sci U S A. 2010;107(17):7886–7891.
   PubMed Web of Science ®Google Scholar
• Lemonnier T, Blanchard S, Toli D, et al. Modeling neuronal defects associated with a lysosomal disorder using patient-derived induced pluripotent stem cells. Hum Moi Genet. 2011;20(18):3653–3666.
   Web of Science ®Google Scholar
• Kohan R, Cismondi IA, Oller-Ramirez AM, et al. Therapeutic approaches to the challenge of neuronal ceroid lipofuscinoses. Curr Pharm Biotechnoi. 2011;12(6):867–883
   PubMed Web of Science ®Google Scholar
• Giugliani R, Federhen A, Muñoz Roj as MV et al. Muc opolysaccharidosi s I, II, and VI: Brief review and guidelines for treatment. Genet Mol Bioi. 2010;33(4):589–604.
   PubMed Web of Science ®Google Scholar
• McGill JJ, Inwood AC, Coman DJ, et al. Enzyme replacement therapy for mucopolysaccharidosis VI from 8 weeks of age - a sibling control study. Clin Genet. 2010;77(5):492–498.
   PubMed Web of Science ®Google Scholar
• Vieira T, Schwartz I, Muñoz V et al. Mucopolysaccharidoses in Brazil: what happens from birth to biochemical diagnosis? Am J Med Genet A. 2008;146A(13):1741–1747.
   Google Scholar
• Alonso-Fernández JR, Fidalgo J, Colón C. Neonatal screening for mucopolysaccharidoses by determination of glycosaminoglycans in the eluate of urine-impregnated paper: preliminary results of an improved DMB-based procedure. J Clin Lab Anal. 2010;24(3):149–153.
   Web of Science ®Google Scholar